From what i understand, the patent was granted to Kannalife on one specific condition:
"Dean Petkanas, chief executive officer at KannaLife Sciences, told us that the exclusivity applies only for the development and sale of cannabinoid based therapeutics as antioxidants and neuroprotectants for use in the treatment of hepatic encephalopathy."
Thanks, I did not realize the importance of KannaLife Sciences. I found the interview with their CEO, Dean Petkanas, revealing. As you point out, their exclusive patent rights pertain to protocols for hepatic encephalopathy. This appears to be a narrow application with a legal cannabinoid solution.
From the interview Mr. Petkanas offers:
Petkanas told us. "Our exclusivity is narrowly focused."
But as far as the specific application covered in the exclusive rights -- for treating hepatic encephalopathy -- Petkanas was animated.
"Phytomedicines are the forefront of treating many diseases," Petkanas told us. "We're looking for specific endpoints."
The KannaLife CEO didn't close the door on possibly working with existing medical cannabis access points, possibly through lab testing for potency and purity, and through improving standardization and labeling.
"We don't want to be involved in the production, growth or dispensing of marijuana at the retail level," Petkanas was quick to clarify. "We just want to help [dispensaries] understand a little better the horticultural sciences involved in it.
"We should regard the plant as medicine and use it accordingly," he said. "But the minute we launch this program, I'm going to have the hate of the pharmaceutical industry come down on my head like white hot rain.
Many of us grasp the import of this last comment.
Our options are networking , revealing the truth, and voting our intentions into place. People are listening.